PIH1D1

Across TCGA pan-cancer cohorts, PIH1D1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PIH1D1 data layer compared with 18 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PIH1D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PIH1D1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, PRAD, and COAD are the cancer types where PIH1D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.112	0.764	<.001	18	view →
PRAD	DFS	Median	All	0.105	0.776	<.001	12	view →
COAD	OS	Median	All	0.208	0.688	.005	6	view →
SKCM	DFS	Median	II,III,IV	0.300	0.692	.034	6	view →
UCEC	OS	Median	All	1.000	0.662	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PIH1D1–LUSC (OS)

Open the LUSC breakdown →